Peripheral Blood Flow Responses to Electromagnetic Energy

Conditions

• Exposure to Man-made Visible Light

Eligibility Criteria

Sex

ALL

Age

18 Years - 59 Years

Healthy Volunteers

Accepted

Interventions

• 670 nm light — DEVICE
  670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
• octafluropropane — DRUG
  Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.

Study Details

This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.

Key Dates

Start date

Nov 30, 2014

Status verified

Apr 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

40 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: 670 nm light
  Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.

Primary Outcome Measure

Change in blood flow (using octafluoropropane infusion and ultrasound) [ Time Frame: 10 minutes ]

Central Contacts

• Nicole L Lohr, MD, PhD
  205-996-3504
  [email protected]

Locations (1)

Find similar trials in Milwaukee, WI